Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
Clinical trial NCT04641442 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04641442
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-18
- Primary completion
- 2025-10-14
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.